| Literature DB >> 20668659 |
Julianne Holt-Lunstad1, Timothy B Smith, J Bradley Layton.
Abstract
BACKGROUND: The quality and quantity of individuals' social relationships has been linked not only to mental health but also to both morbidity and mortality.Entities:
Mesh:
Year: 2010 PMID: 20668659 PMCID: PMC2910600 DOI: 10.1371/journal.pmed.1000316
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Figure 1Flow diagram.
Overview of the 148 studies included in the meta-analysis.
| Source | Total Number of Participants | Average Age at Intake | Location of Study | Study Length | Cause of Mortality | Social Relationship Measure | Original Statistic Metric | lnOR | Standard Error |
| Ahern et al., 1990 | 353 | 50 | USA | 1 y | All-cause | Functional | M & SD | 0.27 | 0.36 |
| Alter et al., 2006 | 3,138 | 64 | Canada | 5 y 4 m | CVD | Combined | Chi | 0.06 | 0.15 |
| Anstey et al., 2002 | 2,065 | 78 | Australia | 9 y | All-cause | Structural | Freq | 0.44 | 0.09 |
| Astrand et al., 1989 | 391 | 50 | Sweden | 22 y | All-cause | Combined | OR | 0.00 | 0.18 |
| Avlund et al., 1998 | 727 | 70 | Denmark | 11 y | All-cause | Combined | OR | 0.40 | 0.16 |
| Avlund et al., 2004 | 565 | 75 | Denmark, Finland | 5 y | All-cause | Structural | OR | 0.54 | 0.22 |
| Barefoot et al., 2005 | 3,109 | 58 | Denmark | 7 y 2 m | All-cause | Structural | p | 0.15 | 0.12 |
| Berkman and Syme, 1979 | 4,765 | 47 | USA | 9 y | All-cause | Structural | Freq | 0.60 | 0.30 |
| Berkman et al., 2004 | 3,495 | 45 | France | 10 y | All-cause | Structural | RR | 1.61 | 0.14 |
| Birket-Smith et al., 1989 | 128 | 73 | Denmark | 1 y | All-cause | Structural | R | 0.37 | 0.33 |
| Blazer, 1982 | 331 | 72 | USA | 2 y 6 m | All-cause | Combined | RR | 1.05 | 0.30 |
| Blazer et al., 2001 | 3,664 | 73 | USA | 3 y | All-cause | Combined | OR | 0.15 | 0.10 |
| Bowling, 1989 | 503 | 73 | UK | 6 y | All-cause | Structural | Chi | 0.51 | 0.16 |
| Brown et al., 2003 | 846 | NR | USA | 5 y | All-cause | Combined | OR | 0.01 | 0.22 |
| Brummet et al., 2005 | 2,711 | 62 | USA | 11 y 1m | All-cause | Functional | p | 0.25 | 0.17 |
| Burg et al., 2005 | 1,899 | 75 | USA | 2 y 5 m | All-cause | Combined | Freq | 1.39 | 0.28 |
| Burns et al., 2005 | 147 | 63 | Australia | 7 y 4 m | Cancer | Combined | Combin | 0.45 | 0.31 |
| Butow et al., 1999 | 125 | 55 | Australia | 2 y | Cancer | Combined | p | 0.35 | 0.33 |
| Bygren et al., 1996 | 12,675 | 43 | Sweden | 9 y | All-cause | Structural | Freq | 0.41 | 0.07 |
| Case et al., 1992 | 1,195 | 59 | Canada, USA | 4 y 2 m | CVD | Structural | RR | 0.68 | 0.25 |
| Cassileth et al., 1988 | 203 | 60 | USA | 8 y | Cancer | Structural | Combin | −0.03 | 0.26 |
| Ceria et al., 2001 | 1,786 | 78 | USA | 6 y | All-cause | Structural | RR | 1.01 | 0.12 |
| Chacko et al., 1996 | 94 | 53 | USA | 4 y 8 m | CVD | Functional | Chi | 0.92 | 0.39 |
| Christensen et al., 1999 | 133 | 29 | USA | 58 y 2m | All-cause | Combined | Chi | 0.98 | 0.32 |
| Christensen et al., 1994 | 78 | 54 | USA | 5 y | All-cause | Functional | Chi | 0.98 | 0.44 |
| Cohen et al., 1987 | 155 | 73 | USA | 3 y | All-cause | Structural | T | 0.65 | 0.30 |
| Colon et al., 1991 | 100 | 30 | USA | 2 y | Cancer | Functional | Chi | 0.86 | 0.38 |
| Cornman et al., 2003 | 4,049 | NR | Taiwan | 3 y | All-cause | Structural | OR | 0.17 | 0.06 |
| Coyne et al., 2001 | 189 | 53 | USA | 4 y | CVD | Functional | RR | 0.99 | 0.26 |
| Cree et al., 2000 | 558 | 82 | Canada | 4 m | All-cause | Functional | OR | 0.30 | 0.34 |
| Cuijpers, 2001 | 424 | 85 | Netherlands | 1 y | All-cause | Functional | OR | −0.10 | 0.31 |
| Dalgard & Haheim, 1998 | 1,002 | 46 | Norway | 17 y | All-cause | Structural | p | 0.23 | 0.15 |
| Devins et al., 1990 | 97 | 40 | Canada | 4 y | Other | Structural | R | −0.025 | 0.38 |
| Dickens et al., 2004 | 556 | 60 | UK | 1 y | CVD | Functional | p | 0.65 | 0.45 |
| Ell et al., 1992 | 294 | 61 | USA | 6 y 11m | All-cause | Combined | p | −0.15 | 0.21 |
| Eng et al., 2002 | 16,242 | 55 | USA | 10 y | All-cause | Structural | RR | 0.42 | 0.06 |
| Engedal,1996 | 334 | 82 | Norway | 3 y | All-cause | Structural | M & SD | 0.62 | 0.20 |
| Farmer et al., 1996 | 320 | 60 | USA | 4 y 7m | All-cause | Combined | RR | 0.81 | 0.22 |
| Forster & Stoller, 1992 | 363 | 74 | USA | 7 y | All-cause | Combined | LnOR | −0.20 | 0.22 |
| Frasure-Smith et al., 2000 | 887 | 59 | Canada | 1 y | CVD | Functional | p | 0.09 | 0.12 |
| Frick et al., 2005 | 99 | 55 | Germany | 3 y 11m | Cancer | Combined | p | 0.23 | 0.35 |
| Fry and Debats, 2006 | 380 | 75 | Canada | 5 y 11m | All-cause | Combined | RR | 0.78 | 0.24 |
| Fuhrer et al., 1999 | 3,777 | 76 | France | 5 y | All-cause | Combined | RR | 0.38 | 0.13 |
| Funch & Marshall, 1983 | 208 | 51 | USA | 20 y | Cancer | Structural | Combin | 0.17 | 0.26 |
| Ganzini et al., 1997 | 100 | 73 | USA | 2 y 6m | All-cause | Combined | Combin | 0.15 | 0.25 |
| Gellert et al., 1993 | 136 | 47 | USA | 10 y | Cancer | Functional | RR | −0.24 | 0.40 |
| Giles et al., 2005 | 1,477 | 80 | Australia | 10 y | All-cause | Structural | p | 0.21 | 0.10 |
| Giraldi et al., 1997 | 74 | 51 | Italy | 6 y | Cancer | Functional | M & SD | 0.14 | 0.43 |
| Glass et al., 1999 | 1,380 | 72 | USA | 13 y | All-cause | Structural | RR | 0.42 | 0.20 |
| Goldman et al., 1995 | 7,478 | 77 | USA | 6 y | All-cause | Structural | OR | 0.30 | 0.06 |
| Goodwin et al., 1996 | 328 | 72 | USA | 10 y | All-cause | Structural | p | 0.62 | 0.20 |
| Gorkin et al.,1993 | 1,146 | 61 | USA | 10 m | All-cause | Functional | Freq | 0.23 | 0.28 |
| Grand et al., 1990 | 645 | 75 | France | 4 y | All-cause | Combined | OR | 0.40 | 0.22 |
| Greenfield et al., 2002 | 5,092 | NR | USA | 11 y | All-cause | Structural | RR | 0.38 | 0.14 |
| Greenwood et al., 1995 | 1,274 | 59 | UK | 4 y | All-cause | Structural | RR | 0.43 | 0.17 |
| Grodner et al., 1996 | 110 | 63 | USA | 6 y | All-cause | Combined | M & SD | 0.50 | 0.35 |
| Gustafsson et al., 1998 | 421 | 81 | Sweden | 6 y | All-cause | Structural | OR | 0.24 | 0.19 |
| Hall et al., 1993 | 5,921 | 60 | Sweden | 11 y | CVD | Structural | OR | 0.23 | 0.15 |
| Helweg-Larsen, 2003 | 6,617 | 44 | Denmark | 13 y | All-cause | Combined | RR | 0.74 | 0.05 |
| Herndon et al., 1999 | 206 | 61 | USA | 4 y 2 m | Cancer | Functional | p | 0.16 | 0.26 |
| Hill et al., 2005 | 3,050 | 78 | USA | 8 y | All-cause | Combined | p | 0.08 | 0.07 |
| Hirdes & Forbes, 1992 | 259 | 45 | Canada | 20 y | All-cause | Combined | RR | 0.55 | 0.29 |
| Ho, 1991 | 946 | 77 | China | 2 y | All-cause | Combined | RR | 0.55 | 0.24 |
| House et al., 1982 | 2,754 | 52 | USA | 12 y | All-cause | Structural | Combin | 0.27 | 0.17 |
| Hummer et al., 1999 | 21,204 | 43 | USA | 8 y | All-cause | Structural | Freq | 0.45 | 0.05 |
| Iribarren et al., 2005 | 5,108 | 25 | USA | 16 y | All-cause | Structural | Combin | 0.60 | 0.21 |
| Irvine et al., 1999 | 634 | 64 | Canada | 2 y | All-cause | Structural | RR | 0.01 | 0.32 |
| Iwasaki et al., 2002 | 11,560 | 55 | Japan | 7 y | All-cause | Combined | RR | 0.22 | 0.11 |
| Johnson et al., 2005 | 3,698 | 43 | USA | 5 y | All-cause | Combined | p | 0.18 | 0.10 |
| Johnson et al., 1996 | 1,257 | 64 | Sweden | 14 y | CVD | Functional | RR | 0.21 | 0.15 |
| Jorm et al., 1991 | 228 | 79 | Australia | 5 y | All-cause | Functional | M & SD | 0.24 | 0.24 |
| Juon et al., 2003 | 1,091 | 6 | USA | 28 y | All-cause | Structural | OR | 0.60 | 0.35 |
| Jylhä and Aro, 1989 | 936 | NR | Finland | 6 y 6 m | All-cause | Combined | p | 0.32 | 0.12 |
| Kaplan et al., 1988 | 5,320 | 49 | Finland | 5 y | All-cause | Structural | OR | 0.75 | 0.18 |
| Kaplan et al., 1994 | 2,501 | 53 | Finland | 5 y 11m | All-cause | Combined | RR | 0.27 | 0.19 |
| Kawachi et al., 1996 | 18,702 | 60 | USA | 4 y | All-cause | Structural | RR | 0.50 | 0.17 |
| Keller et al., 2003 | 654 | 78 | USA | 10 y | All-cause | Structural | p | 0.53 | 0.14 |
| Kiely et al., 2000 | 916 | 87 | USA | 4 y 6 m | All-cause | Structural | p | 0.23 | 0.12 |
| Kimmel et al., 2000 | 174 | 54 | USA | 5 y | All-cause | Functional | p | 0.73 | 0.17 |
| Korten et al., 1999 | 752 | 70 | Australia | 4 y | All-cause | Combined | Combin | 0.20 | 0.13 |
| Krause, 1997 | 2,209 | 68 | UK | 11 y | All-cause | Combined | OR | −0.03 | 0.10 |
| Krause, 2006 | 976 | 74 | USA | 3 y | All-cause | Combined | OR | 0 | 0.18 |
| Kroenke et al., 2006 | 2,835 | 59 | USA | 12 y | All-cause | Structural | RR | 0.45 | 0.22 |
| La Cour et al., 2005 | 734 | 70 | Denmark | 20 y | All-cause | Structural | p | 0.45 | 0.14 |
| Lee & Rotheram-Borus, 2001 | 307 | 38 | USA | 2 y 4 m | Other | Functional | p | 0.54 | 0.21 |
| Lehto et al., 2006 | 101 | 54 | Finland | 9 y | Cancer | Functional | p | 0.97 | 0.38 |
| Lennartsson and Silverstein, 2001 | 463 | 82 | Sweden | 4 y | All-cause | Structural | RR | 0.40 | 0.17 |
| Ljungquist et al., 1995 | 956 | 70 | Sweden | 10 y | All-cause | Combined | OR | 1.03 | 0.16 |
| Lund et al., 2002 | 1,265 | 60 | Denmark | 8 y | All-cause | Structural | p | 0.37 | 0.16 |
| Lund et al., 2000 | 894 | 79 | Denmark | 8 y | All-cause | Structural | OR | 0.30 | 0.21 |
| Lyyra and Heikkinen, 2006 | 206 | 80 | Finland | 10 y | All-cause | Combined | Combin | 0.25 | 0.30 |
| Maier & Smith, 1999 | 513 | 85 | Germany | 6 y | All-cause | Functional | Combin | 0.33 | 0.16 |
| Malmstrom et al., 2001 | 22,236 | 47 | Sweden | 8 y | All-cause | Structural | RR | 0.30 | 0.07 |
| McClellan et al., 1993 | 210 | 55 | USA | 1 y | All-cause | Functional | M & SD | 0.24 | 0.34 |
| Merlo et al., 2000 | 491 | 68 | Sweden | 10 y | All-cause | Combined | Freq | 0.63 | 0.19 |
| Mertens et al., 1996 | 1,869 | 62 | USA | 4 y | All-cause | Structural | M & SD | 0.56 | 0.08 |
| Morris et al., 1993 | 91 | 60 | USA | 10 y | All-cause | Structural | T | 0.81 | 0.40 |
| Murata et al., 2005 | 1,994 | 73 | Japan | 7 y 4 m | All-cause | Combined | p | 0.12 | 0.11 |
| Murberg and Bru, 2001 | 119 | 66 | Norway | 2 y | CVD | Combined | p | 0.27 | 0.34 |
| Musick et al., 2004 | 3,617 | 47 | USA | 7 y 6 m | All-cause | Combined | R | 0.17 | 0.06 |
| Nakanishi and Tatara, 2000 | 1,285 | 74 | Japan | 5 y 6 m | All-cause | Structural | p | 0.26 | 0.10 |
| Nordentoft et al., 1993 | 974 | 41 | Denmark | 10 y | All-cause | Structural | p | 0.42 | 0.12 |
| Olsen et al., 1991 | 1,637 | 79 | Denmark | 15 y 6m | All-cause | Combined | p | 0.14 | 0.11 |
| Oman and Reed, 1998 | 2,023 | 75 | USA | 5 y 7 m | All-cause | Structural | P | 0.20 | 0.11 |
| Orrell et al., 2000 | 60 | 80 | UK | 3 y | All-cause | Combined | p | 0.62 | 0.48 |
| Orth-Gomer and Johnson, 1987 | 17,433 | 49 | Sweden | 6 y | ? | Structural | RR | 1.31 | 0.07 |
| Orth-Gomer and Unden, 1990 | 147 | 57 | Sweden | 10 y | All-cause | Structural | T | 0.86 | 0.40 |
| Ostbye et al., 2006 | 4,012 | 77 | USA | 10 y | All-cause | Combined | OR | 0.54 | 0.09 |
| Oxman et al., 1995 | 232 | 76 | USA | 6 m | CVD | Combined | Combin | 0.33 | 0.46 |
| Parkerson and Gutman, 2000 | 103 | 63 | USA | 1 y | All-cause | Structural | OR | 1.65 | 0.58 |
| Pennix et al., 1997 | 2,829 | 70 | Netherlands | 3 y | All-cause | Combined | Freq | 0.30 | 0.15 |
| Rasulo et al., 2005 | 1,734 | 81 | Denmark | 6 y | All-cause | Structural | p | 0.11 | 0.09 |
| Reuben et al., 1992 | 259 | 73 | USA | 4 y 3 m | All-cause | Combined | R | 0.52 | 0.22 |
| Reynolds et al., 1994 | 1,011 | 53 | USA | 5 y | Cancer | Combined | p | 0.19 | 0.17 |
| Rodriguez-Artalejo et al., 2006 | 251 | 77 | Spain | 7 m | CVD | Structural | p | 0.17 | 0.33 |
| Rosengren et al., 1998 | 717 | 50 | Sweden | 12 y | All-cause | Combined | Freq | 0.64 | 0.28 |
| Roy et al., 1996 | 547 | 80 | USA | 4 y | All-cause | Structural | RR | 0.76 | 0.15 |
| Rozzini et al., 1991 | 1,201 | 73 | Italy | 3 y | All-cause | Structural | Freq | 0.94 | 0.20 |
| Ruberman et al., 1984 | 2,320 | 50 | USA | 3 y | All-cause | Structural | Chi | 0.39 | 0.08 |
| Rutledge et al., 2003 | 7,524 | 71 | USA | 6 y | All-cause | Combined | RR | 0.53 | 0.05 |
| Rutledge et al., 2004 | 503 | 59 | USA | 2 y 4 m | All-cause | Combined | M & SD | 0.99 | 0.37 |
| Saito-Nakaya et al., 2006 | 238 | 62 | Japan | 7 y 6 m | All-cause | Combined | Freq | −0.07 | 0.35 |
| Schoenbach et al., 1986 | 791 | 55 | USA | 2 y | All-cause | Structural | Freq | 0.80 | 0.19 |
| Seeman et al., 1993 | 1,420 | 74 | USA | 5 y | All-cause | Combined | p | 1.83 | 0.17 |
| Shahatahmasebi et al., 1992 | 534 | 72 | UK | 8 y | All-cause | Combined | Chi | 0.40 | 0.16 |
| Shmotkin et al., 2003 | 1,174 | 84 | Israel | 8 y | All-cause | Structural | p | −0.09 | 0.12 |
| Shye et al., 1995 | 455 | 72 | USA | 15 y | All-cause | Structural | Freq | 0.80 | 0.21 |
| Silverstein and Bengston, 1991 | 435 | 67 | USA | 14 y | All-cause | Combined | OR | 0.03 | 0.16 |
| Soler-Vila et al., 2003 | 322 | 54 | USA | 10 y | All-cause | Combined | M & SD | 0.29 | 0.20 |
| Stavraky et al., 1988 | 224 | 59 | Canada | 1 y | Cancer | Combined | Freq | 0.55 | 0.35 |
| Stek et al., 2005 | 476 | 85 | Netherlands | 5 y | All-cause | Functional | p | 0.35 | 0.21 |
| Sturdy et al., 2002 | 1,066 | 53 | UK | 5 y | All-cause | Structural | OR | 0.17 | 0.35 |
| Sugisawa et al., 1994 | 1,943 | 69 | Japan | 3 y | All-cause | Combined | p | 0.03 | 0.19 |
| Sun and Lui, 2006 | 7,938 | 92 | China | 2 y | All-cause | Structural | R | 0.67 | 0.04 |
| Temkin-Greener et al., 2004 | 3,138 | 79 | USA | 2 y | All-cause | Combined | p | 0.21 | 0.10 |
| Thomas et al., 1997 | 424 | 63 | Canada, USA | 3 y 11m | CVD | Functional | M & SD | 0.10 | 0.18 |
| Tucker et al., 1996 | 1,077 | 12 | USA | 41 y | All-cause | Structural | p | 0.27 | 0.12 |
| Vaillant et al., 1998 | 223 | 20 | USA | 25 y | All-cause | Combined | OR | 1.15 | 0.37 |
| Vogt et al., 1992 | 2,396 | 47 | USA | 15 y | All-cause | Structural | p | 0.20 | 0.08 |
| Walter-Ginzburg et al., 2002 | 1,340 | 83 | Israel | 8 y | All-cause | Combined | Freq | 0.23 | 0.11 |
| Waxler-Morrison et al., 1991 | 118 | 45 | Canada | 4 y | Cancer | Structural | p | 0.27 | 0.36 |
| Weihs et al., 2005 | 90 | 52 | USA | 9 y | Cancer | Structural | Combin | 0.61 | 0.40 |
| Welin et al., 2000 | 275 | 55 | Sweden | 10 y | All-cause | Combined | p | 0.44 | 0.22 |
| Welin et al., 1992 | 959 | 60 | Sweden | 12 y | All-cause | Combined | Combin | 0.52 | 0.17 |
| Wilkins, 2003 | 2,107 | 75 | Canada | 6 y | All-cause | Combined | RR | 0.05 | 0.12 |
| Woloshin et al., 1997 | 37 | 67 | Canada | 1 y | All-cause | Functional | OR | 1.87 | 0.61 |
| Yasuda et al., 1997 | 806 | 74 | USA | 5 y | All-cause | Combined | Freq | 0.27 | 0.19 |
| Zuckerman et al., 1984 | 398 | 72 | USA | 2 y | All-cause | Combined | Combin | 0.09 | 0.18 |
Chi, chi-square; Combin, combined statistics; Freq, frequency counts; m, months; M & SD, means and standard deviations; NR, not reported; OR, odds ratio; RR, risk ratio; p, level of statistical significance; t, t-scores; y, years.
Figure 2Contour enhanced funnel plot.
Descriptive coding of the measures used to assess social relationships.
| Type of Measure | Description | Example of Measure | |
|
|
| ||
| Received support | Self-reported receipt of emotional, informational, tangible, or belonging support | • Inventory of Social Supportive Behaviors | |
| Perceptions of social support | Perception of availability of emotional, informational, tangible, or belonging support if needed. | • EPESE support questions | |
| Perception of loneliness | Feelings of isolation, disconnectedness, and not belonging | • Loneliness Scale | |
|
|
| ||
| Marital status | married versus other | • Binary item: Married yes, no• Married, never married, divorced, separated, widowed | |
| Social networks | network density or size, number of social contacts | • Convoy measure | |
| Social integration | Participation in a broad range of social relationships; including active engagement in a variety of social activities or relationships, and a sense of communality and identification with one's social roles. | • Malmo Influence, Contact, & Anchorage Measure | |
| Complex measures of social integration | A single measure that assesses multiple components of social integration such as marital status, network size and network participation. | • Social Network Index | |
| Living alone | Living alone versus living with others | • Binary item: yes, no• Number of people in household | |
| Social isolation | Pervasive lack of social contact or communication, participation in social activities, or confidant | • Social Isolation Scale | |
|
|
| ||
| Multifaceted Measurement | Multiple measures obtained that assess more than one of the above conceptualizations. | ||
Figure 3Forest plot of structural measures.
Random effects metaregression for effect size estimates of structural social relationships.
| Variable | B | SE |
| β |
| (Constant) | 0.535 | 0.238 | 0.02 | 0.00 |
| Participants' average age | −0.002 | 0.002 | 0.49 | −0.06 |
| Participant sex composition | ||||
| 100% Female | 0.038 | 0.066 | 0.57 | 0.04 |
| 100% Male | 0.049 | 0.068 | 0.48 | 0.05 |
| Participant initial health | −0.103 | 0.085 | 0.23 | −0.10 |
| Cause of mortality | ||||
| Cardiovascular disease | 0.081 | 0.161 | 0.61 | 0.03 |
| Cancer | −0.208 | 0.139 | 0.13 | −0.12 |
| Length of follow-up evaluation (y) | −0.003 | 0.005 | 0.54 | −0.05 |
| Measure of social relationships | ||||
| Living alone | −0.265 | 0.106 | 0.013 | −0.18 |
| Marital status | −0.097 | 0.074 | 0.19 | −0.10 |
| Social isolation | −0.144 | 0.178 | 0.42 | −0.05 |
| Social networks | −0.050 | 0.071 | 0.48 | −0.06 |
| Complex measures of integration | 0.255 | 0.095 | 0.007 | 0.20 |
| Geographic region of study | ||||
| Asia | 0.057 | 0.154 | 0.71 | 0.05 |
| Europe | 0.221 | 0.134 | 0.10 | 0.25 |
| North America | 0.057 | 0.134 | 0.69 | 0.07 |
| Statistically controlled estimate | −0.147 | 0.058 | 0.01 | −0.17 |
Age at study initiation.
Contrasted with reports in which males and females were combined.
Individuals with a pre-existing medical condition contrasted with community samples.
Contrasted with all cause and all other causes.
Contrasted with measures of social participation; see Table 2 for descriptions of each kind of measure.
Contrasted with all other world regions combined.
Contrasted with estimates based on raw data.
β, standardized beta; B, unstandardized beta; SE, standard error.
Weighted average effect sizes across different measures of social relationships.
| Type of Measure | k |
| 95% CI | |
|
| Received social support | 9 | 1.22 | [0.91, 1.63] |
| Perceptions of social support | 73 | 1.35 | [1.22, 1.49] | |
| Loneliness (inversed) | 8 | 1.45 | [1.08, 1.94] | |
|
| Living alone (inversed) | 17 | 1.19 | [0.99, 1.44] |
| Marital status (married versus other) | 62 | 1.33 | [1.20, 1.48] | |
| Social isolation (inversed) | 8 | 1.40 | [1.06, 1.86] | |
| Social networks | 71 | 1.45 | [1.32, 1.59] | |
| Social integration | 45 | 1.52 | [1.36, 1.69] | |
| Complex measures of social integration | 30 | 1.91 | [1.63, 2.23] | |
|
| Multifaceted measurement | 67 | 1.47 | [1.34, 1.60] |
These analyses shifted the units of analysis, with distinct effect size estimates within studies used within different categories of measurement, such that many studies contributed more than one effect size but not more than one per category of measurement.
OR, odds ratio, transformed from random effects weighted lnOR.
Figure 4Forest plot of functional measures.
Figure 5Forest plot of combined measures.
Figure 6Comparison of odds (lnOR) of decreased mortality across several conditions associated with mortality.
Note: Effect size of zero indicates no effect. The effect sizes were estimated from meta analyses: ; A = Shavelle, Paculdo, Strauss, and Kush, 2008 [205]; B = Critchley and Capewell, 2003 [206]; C = Holman, English, Milne, and Winter, 1996 [207]; D = Fine, Smith, Carson, Meffe, Sankey, Weissfeld, Detsky, and Kapoor, 1994 [208]; E = Taylor, Brown, Ebrahim, Jollife, Noorani, Rees et al., 2004 [209]; F, G = Katzmarzyk, Janssen, and Ardern, 2003 [210]; H = Insua, Sacks, Lau, Lau, Reitman, Pagano, and Chalmers, 1994 [211]; I = Schwartz, 1994 [212].